GlassScriptPhysician profile
James R Ampil
NPI 1831131721
$1,976.48
in general payments reported to CMS, 2019-2025
19 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $31.53 · 2021: $123 · 2022: $333 · 2023: $572 · 2024: $248 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.20 | 2021-2025 | Ubrelvy, Qulipta, Synthroid |
| Amgen INC. | $260.61 | 2019-2025 | Evenity, Repatha, Repatha |
| Lilly USA, LLC | $199.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $181.28 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.72 | 2019-2023 | Xifaxan |
| Pfizer INC. | $120.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $91.53 | 2021-2023 | Belsomra |
| Cleerly, INC. | $84.43 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Phathom Pharmaceuticals, INC. | $77.20 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $75.64 | 2019-2022 | |
| Abbott Laboratories | $72.09 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $67.38 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $59.62 | 2021 | |
| Novo Nordisk INC | $53.48 | 2023-2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $45.67 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $18.70 | 2020 | |
| Antares Pharma, INC. | $17.13 | 2019 | |
| Astellas Pharma US INC | $16.33 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ampil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.